COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,627 Articles (22,913 medRxiv, 8,714 bioRxiv)

Most recent first Previous |  Page 734: Articles 7331-7340  | Next

Determinants of healthcare employee preference to continue teleworking after the COVID-19 pandemic: a cross-sectional study using hierarchical regression
Jones, A. M., Fan, J., Thomas-Olson, L., Zhang, W., McLeod, C. B.
10.1101/2022.07.18.22277694 — Posted: 2022-07-19
Discovering host protein interactions specific for SARS-CoV-2 RNA genome
Giambruno, R., Zacco, E., Ugolini, C., Vandelli, A., Mulroney, L., D'Onghia, M., Criscuolo, E., Castelli, M., Clementi, N., Clementi, M., Mancini, N., Bonaldi, T., Gustincich, S., Leonardi, T., Tartaglia, G. G., Nicassio, F.
10.1101/2022.07.18.499583 — Posted: 2022-07-19
Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
Parham, K. A., Kim, G. N., Saeedian, N., Ninkov, M., Richer, C. G., Li, Y., Wu, K., Rashu, R., Barr, S. D., Arts, E. J., Haeryfar, S. M. M., Kang, C. Y., Troyer, R. M.
10.1101/2022.07.19.500626 — Posted: 2022-07-19
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron subvariants BA.2, BA.2.12.1 and BA.5
Fang, Z., Chen, S.
10.1101/2022.07.19.500616 — Posted: 2022-07-19
90K/LGALS3BP Expression is Upregulated in COVID-19 but Does Not Restrict SARS-CoV-2 Infection
Bosquillon de Jarcy, L., Akbil, B., Leyens, J., Postmus, D., Harnisch, G., Jansen, J., Schmidt, M., Aigner, A., Pott, F., Chua, R. L., Krist, L., Gentile, R., Muehlemann, B., Jones, T. C., Niemeyer, D., Fricke, J., Keil, T., Pischon, T., Janke, J., Conrad, C., Iacobelli, S., Drosten, C., Corman, V. M., Ralser, M., Eils, R., Kurth, F., Sander, L. E., Goffinet, C.
10.1101/2022.07.18.22277255 — Posted: 2022-07-19
COVID-associated pulmonary aspergillosis in immunocompetent patients
Ribeiro, H. A. L., Scindia, Y., Mehrad, B., Laubenbacher, R.
10.1101/2022.07.18.500514 — Posted: 2022-07-19
Orally administered niclosamide-based organic/inorganic hybrid suppresses SARS-CoV-2 infection
Jin, G.-w., Choi, G., N, S. R., Piao, H., Ryu, Y. B., Kwon, H.-J., Lee, I. C., Choy, J.-H.
10.1101/2022.07.19.500639 — Posted: 2022-07-19
Impact of SARS-Cov-2 on Clinical Trial Unit Staff: The EPIC Observational Study
Phiri, P., Yardley, L., Elliot, K., Barnard-Kelly, k., Raymont, V., Rathod, S., Hu, J., Cavalini, H., Shi, J., Delanerolle, G.
10.1101/2022.07.18.22277769 — Posted: 2022-07-19
Co-designing an intervention to strengthen vaccine uptake in Congolese migrants in the UK (LISOLO MALAMU): a participatory study protocol
Crawshaw, A. F., Hickey, C., Lutumba, L. M., Kitoko, L. M., Nkembi, S. L., Knights, F., Ciftci, Y., Goldsmith, L. P., Vandrevala, T., Forster, A. S., Hargreaves, S.
10.1101/2022.07.19.22277798 — Posted: 2022-07-19
Adjusting non-pharmaceutical interventions based on hospital bed capacity using a multi-operator differential evolution
Mendoza, V. M. P., Mendoza, R., Lee, J., Jung, E.
10.1101/2022.07.17.22277729 — Posted: 2022-07-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).